TP Introduces ‘Future Forward' Strategy to Accelerate Transformation and Growth
PARIS--(BUSINESS WIRE)--Regulatory News:
TP (Paris:TEP), a global leader in digital business services, unveils 'Future Forward,' its new strategic plan at a Capital Markets Day in New York City. 'Future Forward' is TP's strategic initiative to become a next-generation, AI-enabled company. This encompasses fusing cutting-edge technology with human expertise to expand growth and deliver long-term value. By intelligently orchestrating AI with human empathy, judgement and expertise, TP aims to create competitive advantages for its clients through digital integrated business services.
TP is launching TP.ai FAB (Foundational AI Backbone), a proprietary AI orchestration platform designed to seamlessly integrate artificial intelligence, human expertise, and automation at scale. TP.ai FAB will underpin TP's three pillar growth strategy:
growing the core business with AI: leveraging technology and AI to deliver enhanced client outcomes, strengthen value propositions, and accelerate growth.
extending vertical plays: expanding industry-specific solutions, end-to-end AI-enabled offerings and scaling specialized services globally.
unlocking new opportunities in AI: accelerating growth in markets across the AI value chain, focusing on data services, technology, consulting, and digital marketing.
TP plans to significantly invest over the next three years to accelerate AI deployment supported by a strengthened leadership structure to drive execution.
Together, these initiatives position TP to harness the full potential of its human and technological capabilities, expanding the Group's total addressable market, including new markets, scaling high-margin business models and delivering meaningful value to clients.
Daniel Julien, Founder and CEO of TP, commented: ' TP's growth story has always been shaped by bold pivots at key moments of industry disruption. With each wave of change, we have adapted, transformed and won. We have consistently demonstrated our ability to lead through transformation, setting the pace in a market where we continue to outperform. With our new strategic plan, rooted in a powerful human-AI hybrid approach and a resilient business model powered by exceptional AI-ready teams and reinforced governance, we are well-positioned to achieve ambitious yet realistic financial goals and deliver long-term value for our shareholders.'
Thomas Mackenbrock, Deputy CEO of TP, added: 'TP is a global leader in digital business services with a strong track record. To build on this foundation and strengthen our long-term leadership, we are accelerating the transformation of the Group by harnessing the full potential of artificial and human intelligence. Our new strategic plan 'Future Forward', is designed to strengthen our core services portfolio, extend our vertical plays and capture new opportunities along the AI value chain. Our goal is clear: accelerate growth, expand margins and generate substantial cash flow to support strategic investments and return value to shareholders. This is the TP of tomorrow: the preferred AI-enabled strategic partner, creating relentless competitive advantage for our clients.'
Expanding capabilities through strategic partnerships and acquisitions
TP is expanding its AI capabilities through strategic partnerships and acquisitions. The Group has launched an AI partnership program with planned investments of up to €100 million in 2025. This initiative has already led to collaborations with leading AI pioneers:
Sanas, a real-time speech understanding company;
Parloa, a leading AI agent management platform for customer service, and;
Ema, a cutting-edge agentic AI platform.
TP also announced today the acquisition of 'Agents Only', an AI-enabled crowdsourcing platform for on-demand highly skilled domain experts across the world.
'Agents Only' provides a flexible talent infrastructure for the AI era, sourcing and managing thousands of AI-literate annotators, data scientists, and domain specialists. This acquisition will enhance TP's access to certified professionals at scale, accelerating project delivery and improving service quality across data labeling, data annotation, and generative AI support activities. 'Agents Only' and other new AI solutions will be seamlessly integrated into the TP.ai FAB platform to ensure scalability and speed to market.
For additional information on the acquisition of Agents Only, please refer to the press release issued today, June 18, 2025, which can be found here.
TP and Carnegie Mellon University forge alliance to accelerate applied research for AI -Human augmentation
TP is joining forces with Carnegie Mellon University's world-renowned School of Computer Science to accelerate AI research and innovation. To highlight this collaboration, Professor Martial Hebert, Dean of the School of Computer Science at CMU, is joining TP executives for a fireside chat at the Group's Capital Markets Day, offering his perspective on the evolving landscape of AI.
Medium-term outlook for 2028
TP announces the following financial objectives for the next three years (2026-2028):
Returning to sustained mid-single digit like-for-like 1 revenue yearly growth with 4-6% in 2028
Recurring EBITA margin at ~15.5% in 2028, expected post AI transformation
Generating cumulative net free cash flow of ~€3 billion including organic AI efforts incurred over 2026-2028
Capital allocation priorities over the period are as follows:
Investing ~20% of the net free cash flow to accelerate investments in AI and transformation, including strategic partnerships and selective bolt-on acquisitions
Further strengthening TP's balance sheet with high financial flexibility and targeting net debt leverage ratio of 1.2x EBITDA in 2028
Returning to shareholders ~50% of the net free cash flow or ~€1.5 billion, through dividends (dividend policy maintained) and share buybacks
1 At constant scope and exchange rates
Capital Markets Day 2025 details
At TP's Capital Markets Day, CEO Daniel Julien, Deputy CEO Thomas Mackenbrock and members of the management team will present the Group's strategic priorities and medium-term financial outlook. An AI technology showcase, featuring TP's AI solutions and TP's AI partners solutions, will be presented at the event for in-person attendees.
The event begins at 9:00 am ET / 3:00 pm CET and can be viewed virtually here https://tp.engagestream.companywebcast.com/capital-markets-day-2025
All the documentation related to the CMD is available on the Group's website (www.tp.com):
Investor days: Events and publications | TP
--------------------------
Disclaimer
All forward-looking statements are based on TP management's present expectations of future events and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For a detailed description of these factors and uncertainties, please refer to the 'Risk Factors' section of our Universal Registration Document, available at www.tp.com. TP undertakes no obligation to publicly update or revise any of these forward-looking statements.
Indicative investor calendar
Capital Markets Day: June 18, 2025
First-Half 2025 Results: July 31, 2025
Third-Quarter 2025 Revenue: November 5, 2025
ABOUT TELEPERFORMANCE GROUP
Teleperformance (TEP – ISIN: FR0000051807 – Reuters: TEPRF.PA - Bloomberg: TEP FP), is a global leader in digital business services which consistently seeks to blend the best of advanced technology with human empathy to deliver enhanced customer care that is simpler, faster, and safer for the world's biggest brands and their customers. The Group's comprehensive, AI-powered service portfolio ranges from front office customer care to back-office functions, including operations consulting and high-value digital transformation services. It also offers a range of specialized services such as collections, interpreting and localization, visa and consular services, and recruitment process outsourcing services. The teams of multilingual, inspired, and passionate experts and advisors, spread in close to 100 countries, as well as the Group's local presence allows it to be a force of good in supporting communities, clients, and the environment. In 2024, Teleperformance reported consolidated revenue of €10,280 million (US$11 billion) and net profit of €523 million.
Teleperformance shares are traded on the Euronext Paris market, Compartment A, and are eligible for the deferred settlement service. They are included in the following indices: CAC 40, STOXX 600, S&P Europe 350, MSCI Global Standard and Euronext Tech Leaders. In the area of corporate social responsibility, Teleperformance shares are included in the CAC 40 ESG since September 2022, the Euronext Vigeo Euro 120 index since 2015, the MSCI Europe ESG Leaders index since 2019, the FTSE4Good index since 2018 and the S&P Global 1200 ESG index since 2017.
For more information: www.tp.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
10 hours ago
- Business Wire
EMEREN GROUP INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Emeren Group Ltd.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Emeren Group Ltd. (NYSE: SOL) to Shurya Vitra Ltd. Under the terms of the proposed transaction, shareholders of Emeren Group will receive $0.20 in cash per ordinary share or $2.00 in cash per American Depositary Share. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Business Wire
10 hours ago
- Business Wire
COUCHBASE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Couchbase, Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Couchbase, Inc. (NasdaqGS: BASE) to Haveli Investments. Under the terms of the proposed transaction, shareholders of Couchbase will receive $24.50 in cash for each share of Couchbase that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Business Wire
11 hours ago
- Business Wire
OrsoBio to Present Preclinical Data on Mitochondrial Protonophore Portfolio in Models of Obesity at the American Diabetes Association's 85th Scientific Sessions
MENLO PARK, Calif.--(BUSINESS WIRE)--OrsoBio, Inc. ('OrsoBio' or 'the Company'), a clinical-stage biopharmaceutical company developing treatments for obesity and obesity-associated disorders, today announced new preclinical data being presented at the 85th Scientific Sessions of the American Diabetes Association (ADA) being held June 20-23, 2025, in Chicago, Ill. The Company will present three abstracts highlighting the efficacy of its mitochondrial protonophores to induce weight loss and provide glycemic benefits while preserving lean mass in diet-induced obese (DIO) mice. The studies demonstrate the potential of TLC-6740 and TLC-1180—as monotherapy and in combination with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide—for both the induction and maintenance of weight loss following incretin treatment. 'The mechanism of our mitochondrial protonophores to increase energy expenditure complements that of incretins to enhance and sustain weight loss and provide additive metabolic benefits,' said Mani Subramanian, MD, PhD, Chief Executive Officer of OrsoBio. 'These preclinical findings mark an important step in fulfilling our mission to develop innovative, effective, oral therapies for obesity that preserve muscle and support cardiometabolic health.' OrsoBio is advancing a pipeline of novel therapies targeting obesity through mechanistically distinct and complementary approaches. The Company's lead candidates include TLC-6740 and TLC-1180, both mitochondrial protonophores that promote weight loss by increasing energy expenditure. In addition, OrsoBio is developing TLC-3595, a selective inhibitor of acetyl-CoA carboxylase 2 (ACC2), designed to enhance fat oxidation. "GLP-1 receptor agonists have transformed obesity treatment but are limited by gastrointestinal side effects and loss of muscle mass,' said Rob Myers, MD, Chief Medical Officer of OrsoBio. 'Our preclinical data show that our mitochondrial protonophores drive sustained, fat-selective weight loss and metabolic benefits when combined with or sequenced after GLP-1 receptor agonists. These findings support our ongoing Phase 1b study of TLC-6740 in combination with tirzepatide (NCT05822544)." Poster information: Sequential Combination of the Mitochondrial Protonophore TLC-6740 With Semaglutide Normalizes Body Weight and Preserves Lean Mass in DIO Mice Abstract #1687-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT) This preclinical study assessed TLC-6740 alone, in combination with low-dose semaglutide (sequential combination), and as maintenance therapy following semaglutide discontinuation in DIO mice. The sequential combination of TLC-6740 with low-dose semaglutide produced superior body weight and fat mass loss, and improved glycemic parameters compared with TLC-6740 alone and high-dose semaglutide. Initiating TLC-6740 after semaglutide discontinuation maintained body weight and fat mass loss, and glycemic benefits. These findings support evaluation of TLC-6740 in combination with incretins in people living with obesity; a 24-week combination study of TLC-6740 with tirzepatide is ongoing (NCT05822544). De Novo or Sequential Combination of the Mitochondrial Protonophore TLC-1180 With Semaglutide Improves Weight Loss and Preserves Lean Mass in DIO Mice Abstract #1694-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT) This preclinical study evaluated the effects of TLC-1180 alone, in combination with semaglutide, and as a maintenance treatment following semaglutide discontinuation in DIO mice. As monotherapy, TLC-1180 demonstrated body weight and fat mass loss and preserved lean mass. Body weight and fat mass loss were amplified, and lean mass was preserved with TLC-1180 in combination with semaglutide. These benefits persisted when TLC-1180 was used as a maintenance treatment after semaglutide discontinuation. These data highlight the potential of TLC-1180 as monotherapy, in combination with incretins, or as maintenance therapy post incretin discontinuation in people living with obesity. Novel Combination of a Mitochondrial Protonophore and an Acetyl-CoA Carboxylase 2 (ACC2) Inhibitor Causes Weight Loss and Preserves Lean Mass in Obese Mice Abstract #1686-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT) This preclinical study evaluated the effects of the mitochondrial protonophore, TLC-1180, and the ACC2 inhibitor, TLC-3595—as monotherapy and in combination—and semaglutide in DIO mice. TLC-3595 dose dependently reduced body weight, fat mass, and liver biochemistry while preserving lean mass in DIO mice. A combination of TLC-3595 with TLC-1180 had similar weight loss efficacy to semaglutide, but preserved lean mass. Taken together, these data suggest that the novel, all-oral, non-incretin combination of TLC-3595 and TLC-1180 may cause similar weight loss to incretins and may afford additional advantages, including improved weight loss quality and/or tolerability (e.g., reduced incidence of gastrointestinal adverse events). About TLC-6740 TLC-6740 is a novel, oral, liver-targeted mitochondrial protonophore in development for the treatment of obesity and obesity-associated diseases, including diabetes and MASH. Based on active hepatic uptake and mitochondrial protonophore activity, TLC-6740 increases energy expenditure in hepatocytes, and is expected to have broad, systemic metabolic and cardiovascular benefits, including weight loss, improved insulin sensitivity, and as a treatment for MASH, and dyslipidemia. TLC-6740 is currently being evaluated in a Phase 1b clinical trial, as monotherapy and in combination with tirzepatide, in patients living with obesity (NCT05822544). About TLC-1180 TLC-1180 is a novel, potent, long-acting mitochondrial protonophore that has been shown to increase energy expenditure in mice with diet-induced obesity (DIO). In preclinical studies of DIO mice, TLC-1180 induced weight loss, improved glucose control, and enhanced the efficacy of GLP-1 receptor agonists, both as a single agent and in combination with incretins. TLC-1180 is currently completing IND-enabling studies and a first-in-human study is expected to initiate in 2025. About TLC-3595 TLC-3595 is a novel and selective ACC2 inhibitor designed to treat obesity and type 2 diabetes by increasing fatty acid oxidation (FAO), reducing ectopic lipid accumulation, and improving insulin sensitivity in skeletal muscle and liver. The compound may also have potential as a treatment for other conditions characterized by impaired FAO, including heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction-associated steatohepatitis (MASH). About OrsoBio, Inc. OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat obesity and obesity-associated disorders, including type 2 diabetes, MASH, and severe dyslipidemias. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism. For more information, please visit
